Home page  |  Help  |  Clear
English  |  French
 Search  |  Categories  |  Titles A-Z  |  Countries  |  Compare countries  |  Index  
Full TOC
Expand Document
Expand Chapter
Preferences

close this bookThe Kenya National Drug Policy (WHO; 1994; 27 pages)
View the documentFOREWORD
View the documentABBREVIATIONS
Open this folder and view contents1. GOAL AND OBJECTIVES OF THE NATIONAL DRUG POLICY
Open this folder and view contents2. PUBLIC SECTOR DRUG SUPPLY
Open this folder and view contents3. DRUG SUPPLY BY THE PRIVATE SECTOR & NON-GOVERNMENTAL ORGANISATIONS
Open this folder and view contents4. VETERINARY DRUG SUPPLY
close this folder5. REGULATORY CONTROL
View the document5.1. Drug Control and Administration
View the document5.2. Drug Registration
View the document5.3. Scheduling of Drugs
View the document5.4. Pharmaceutical Inspectorate
View the document5.5. Clinical Trials
View the document5.6. Traditional Medicine
View the document5.7. Professional Associations and Professional Ethics
Open this folder and view contents6. RATIONAL DRUG USE
Open this folder and view contents7. QUALITY ASSURANCE
View the document8. DRUG ABUSE
Open this folder and view contents9. IMPORTATION AND EXPORTATION OF DRUGS
Open this folder and view contents10. LOCAL PRODUCTION
View the document11. MANPOWER TRAINING AND DEVELOPMENT
View the document12. LEGISLATION
View the document13. MONITORING & EVALUATION
View the document14. INTERSECTORAL AND TECHNICAL COOPERATION
 

5.2. Drug Registration

Pharmaceutical products intended both for the Kenya market as well as products intended for export will be registered with the Pharmacy and Poisons Board. The following criteria will be used in the registration:

(1) Proven quality, safety and efficacy.

(2) Specific medical need; new drug entities and drug combinations should have an added advantage over the already registered product.

(3) Proposed wholesale and retail prices; products whose prices are excessive compared to those already registered for the same therapeutic indications will not be accepted.

(4) Unique characteristic of the drug product such as life-saving and orphan drugs. Orphan drugs are products for rare conditions for which the small size of the local market would make registration otherwise commercially unattractive.


The registration fee will be waived for orphan drugs. New investigational drugs will be considered for exemption from normal registration requirements in order to facilitate their availability for clinical studies.

to previous sectionto next section

Please provide your feedback
Abbreviations
English  |  French